The first patent, which was issued in 2012, covers the use of ion exchange resins in immediate-release and extended-release oral dosage forms.
Issued in 2013, the second patent covers the use of ion exchange resins in immediate-release and extended-release oral formulations of benzonatate, a non-narcotic prescription cough product.
The royalty stream includes milestone payments and has an estimated net present value of $7.5m.
Either of the patents or both along with the royalty stream will be sold at the sealed bid sale, according to Alitair.